As advised via PHARMAC Tender Results of June 2019 there is to be a change in the listing and future sole supply of Fluoxetine.

New listing from 1 November 2019

Fluoxetine Cap 20 mg, 84 capsule pack                                                      Pharmacode 2353121                       Schedule price $2.91

Fluoxetine Tab dispersible 20 mg scored, 30 tablet blister pack                                 Pharmacode 2077817                    Schedule price $1.98

Incumbent brand Teva

Fluoxetine-Arrow Tab 20 mg, 90 capsule pack                                                    Pharmacode 2450860                         Schedule price $1.99

Fluoxetine-Arrow Tab dispersible 20 mg scored, 30 tablet blister pack                    Pharmacode 2450879                    Schedule price $2.47

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 April 2020.

No Brand switch fee notified at the time of notification.

As of the date of this notification ProPharma / PWR cannot accept Fluoxetine-Arrow for credit under any circumstances.

From 1 November 2019 community pharmacies dispensing Fluoxetine will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted reducing all risk where practical.

There may well be some financial benefit in staying with incumbent while stocks remain available however there is also associated risk.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 April 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 April 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.


About The Author